Breaking Finance News

Zacks Investment Research announced Merit Medical Systems, Inc. (NASDAQ:MMSI), boosting its stock price target to $41.00 today

Just yesterday Merit Medical Systems, Inc. (NASDAQ:MMSI) traded -0.72% lower at $37.00. Merit Medical Systems, Inc.’s 50-day moving average is $40.79 and its 200-day moving average is $35.09. The last stock price is up 17.69% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 4,772 shares of MMSI traded hands, down from an average trading volume of 388,891

In a report released on 06/22/2017 Zacks Investment Research increased the stock price target of Merit Medical Systems, Inc. (NASDAQ:MMSI) to $41.00 reporting a possible upside of 0.11%.

Previously on Tuesday June 20, 2017, SunTrust released a statement about Merit Medical Systems, Inc. (NASDAQ:MMSI) increased the target price from $0.00 to $43.00. At the time, this indicated a possible upside of 0.19%.

Recent Performance Chart

Merit Medical Systems, Inc. (NASDAQ:MMSI)

Merit Medical Systems, Inc. has 52 week low of $20.70 and a 52 week high of $42.60 with a PE ratio of 58.83 and has a market capitalization of $0.

Brief Synopsis On Merit Medical Systems, Inc. (NASDAQ:MMSI)

Merit Medical Systems, Inc. is a manufacturer and marketer of disposable medical devices used in a range of interventional, diagnostic and therapeutic medical procedures. The Company operates in two segments: cardiovascular and endoscopy. The cardiovascular segment consists of cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases, and includes embolotherapeutic, cardiac rhythm management (CRM), electrophysiology (EP), and interventional oncology and spine devices. Its endoscopy segment consists of gastroenterology and pulmonology medical devices, which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Within its segments, the Company offers products focused in four product groups: peripheral intervention, cardiac intervention, interventional oncology and spine, and endoscopy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.